Prostate Cancer
Initial Experience with [177Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction.
September 23, 2024
Beyond Medical Bills: The Indirect Costs of Prostate Cancer.
September 23, 2024
Stereotactic radiotherapy for localized prostate cancer: 10-year outcomes from three prospective trials.
September 20, 2024
Lipid Metabolism Modulatory Cisplatin Prodrug Sensitizes Resistant Prostate Cancer toward Androgen Deprivation Therapy.
September 20, 2024
Ipilimumab with Nivolumab in molecular-Selected patients with castration-resistant PRostate cancer: primary analysis of the Phase 2 INSPIRE trial.
September 20, 2024
Secondary Cancer in Prostate Cancer Patients Treated With Advanced External Beam Radiation Therapy.
September 20, 2024
A Common Culprit Drives Prostate Cancer Progression
September 19, 2024
Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing.
September 19, 2024
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).
September 19, 2024
Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer.
September 19, 2024
Prediction of undetectable circulating tumor DNA by comprehensive genomic profiling assay in metastatic prostate cancer: the SCRUM-Japan MONSTAR SCREEN project.
September 19, 2024
Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance.
September 19, 2024
Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer.
September 19, 2024
BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity.
September 19, 2024